ESPE Abstracts (2024) 98 P1-150

ESPE2024 Poster Category 1 Fat, Metabolism and Obesity 3 (10 abstracts)

Heterozygous Familial Hypobetalipoproteinemia: description of phenotype in affected children and adolescents in the Era of Obesity.

Patrizia Bruzzi 1 , Giulia Cammarata 2 , Anna Rita Di Biase 1 , Antonio Colecchia 3 & Lorenzo Iughetti 4


1Pediatric Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy. 2Post-graduate School of Pediatrics, Department of Medical and Surgical Sciences of the Mother, Children and Adults, University of Modena and Reggio Emilia, Modena, Italy. 3Division of Gastroenterology, Azienda Ospedaliero-Universitaria di Modena and University of Modena and Reggio Emilia, Modena, Italy. 4Pediatric Unit, Department of Medical and Surgical Sciences of the Mother, Children and Adults, University of Modena and Reggio Emilia, Modena, Italy


Background: Hypobetalipoproteinemias (HBL) is a heterogeneous group of disorders characterized by reduced plasma levels of total cholesterol (TC), low density lipoprotein-cholesterol (LDL-C) and apolipoprotein B (ApoB). Familial hypobetalipoproteinemia (FHBL) is the most frequent monogenic form of HBL with a dominant mode of inheritance. It may be due to loss-of-function mutations in APOB or, less frequently, in other genes. Heterozygous patients are often asymptomatic, but the genetic mutation causes a defect of exportation of VLDL from the hepatocytes that remain stuck in the liver causing firstly steatosis and/or steatohepatitis and then, fibrosis and cirrhosis. In childhood, the diagnosis of FHBL is often underestimated and guidelines are still lacking.

Aims: The aim of the study is to describe the phenotypic features of a cohort of children and adolescents with a genetic confirmed FHBL attending our pediatric lipid clinic.

Methods: This is a monocentric, observational study collecting anamnestic, anthropometric, biochemical (lipid and glucose profile, liver function) and instrumental (liver ultrasound and elastographic profile) data in children and adolescents with a genetically confirmation of heterozygous FHBL.

Results: 12 children and adolescence (4 females), aged 12.14 ± 1.80 years, were genetically diagnosed with heterozygous FHBL (9/12 carrying a mutation on ApoB gene, 2/12 on ANGPTL8 gene and one case with a mutation on MYLIP gene). At diagnosis, overweight and/or obesity were identified in 7/12 cases. Only one patient was fully asymptomatic. In all cases, lipid assessment was suggestive of FHBL (mean TC 80.41 ± 14.81 and LDL-C 31.54 ± 12.88 mg/dl) independently from BMI SDS (obese vs. normal-weight patients: p 0.62 and 0.39, respectively). In 6/12 patients, steatosis was graded from moderate to severe, mainly when accompanied by overweight and/or obesity (p 0.05). Moreover, transient elastography, an indirect surrogate of fibrosis, was more elevated in FHBL patients if overweight and/or obese (5.65 ± 0.71 vs. 4.60 ± 0.28, p 0.06).

Conclusion: Our data document an unexpectedly wide phenotype of FHBL in childhood and adolescence with a high percentage of overweight or obesity. Moreover, we document a frequent precocious hepatic involvement in FHBL children, especially if obese and overweight, with a potential rapid evolution in fibrosis. In conclusion, even if these preliminary data require the confirmation from sizable cohort, they support the need of a precocious diagnosis of FHBL in childhood that could let to early plan a personalized follow up. Overweight or obesity seem to be concurrent risk factors for a rapid progression of liver damage.

Volume 98

62nd Annual ESPE (ESPE 2024)

Liverpool, UK
16 Nov 2024 - 18 Nov 2024

European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.